• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Abpro Therapeutics on deck for IPO biospectrumasia
    April 16, 2018
    Co-lead candidates are ABP-100 and ABP-201, both tetravalent antibodies, meaning they bind to two different targets with two distinct binding sites per target.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service